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ABSTRACT
Introduction: Cellulitis recurrences are
frequent, difficult to manage, and contribute
considerably to overall disease burden. This
retrospective cases series reports recurrence
rates of first community-acquired lower limb
disease episode initially treated with
daptomycin.
Methods: Treatment consisted of a 21-day two
substances sequential scheme: intravenous
daptomycin (4 mg/kg/day) during
hospitalization and roxithromycin (2 9 150 mg
per os) afterwards. Primary study end-point was
the rate of recurrences during follow-up;
recurrence rates and their binomial 95%
confidence intervals (CI) were calculated with
SPSS 22.0. Recurrences were identified by (1)
review of hospital records and (2) telephone
questionnaires.
Results: Twenty-seven patients hospitalized for
first lower limb cellulitis episodes were started
on daptomycin and 26 patients completed the
above three-week sequential treatment scheme.
During follow-up (range 37–85 months) one
recurrence occurred among the 26 patients
who completed the treatment: 96.2% of these
patients remained relapse free at the end of
follow-up (CI 79.5–99.9%). Considering also
treatment failure, the overall effectiveness of
this combination treatment was 92.6%
recurrence free after more than 3 years
follow-up (25/27 patients; CI 75.5–99.0%).
This study is limited by retrospective planning
and the restricted number of included patients.
Conclusion: The choice of the treatment for
the initial lower limb cellulitis episode may
impact the risk of disease recurrences. Future
studies should explore interventions for the first
cellulitis episode as a means to modify the risk
of the recurring course of this disease.
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INTRODUCTION
Cellulitis is a common bacterial skin infection
that involves the lower extremities in[70% of
cases [1, 2]. Recurrences are frequent affecting
15–40% of patients in the first 3 years and
constitute a significant risk factor for further
disease episodes [1, 3]. Common causative
agents comprise Gram-positive aerobes,
particularly Streptococci (groups A, B, C and G)
and Staphylococcus aureus [2, 4]. Widely used
recommendations for initial empirical
treatment include short schemes (5–10 days)
with beta-lactam antimicrobials [2].
This retrospective case series reports a
reasonably low recurrence rate in patients
treated with a 3-week sequential
daptomycin-roxithromycin scheme for the
initial lower limb cellulitis episode.
METHODS
Adult patients hospitalized in the Dermatology
Clinic of the Ioannina University Hospital
between January 2008 and December 2011 for
the first episode of community-acquired lower
limb cellulitis were treated sequentially with
intravenous daptomycin (4 mg/kg/day;
Cubicin, Novartis Pharmaceuticals, UK, Ltd)
during hospitalization and roxithromycin per
os (2 9 150 mg daily; Rulid, Sanofi-Aventis
A.E.B.E., Greece) for a total of three weeks.
Cases requiring hospitalization (for treatment
strategy of patients with cellulitis in this
hospital see also [3]) were defined as patients
with clinical findings of cellulitis (unilateral,
relatively demarcated area of expanding skin
inflammation, with malaise, fever or chills) and
an abnormal result in at least one of the
following tests: total white blood cell (WBC)
count (normal range: 4500–10,500 cells/lL),
serum C-reactive protein (CRP) level (normal
range\6 mg/L) or erythrocyte sedimentation
rate (ESR; normal range\20 mm/h). Only
patients who completed treatment were
considered in the recurrences analysis. Primary
study end-point was the rate of recurrences
during follow-up after treatment, that is,
cellulitis in the same lower limb diagnosed
more than 1 month after treatment of the first
disease episode. Recurrences were identified by
(1) hospital records (archived patients’ files) of
cellulitis admissions and (2) telephone
questionnaires conducted in February 2012
and February 2015. Recurrence rates and their
binomial 95% confidence intervals (CIs) were
calculated with SPSS 22.0 software package
(SPSS Inc., Chicago, IL, USA). Moreover,
employing the mean individualized 2 years
follow-up recurrence probabilities of lower leg
cellulitis according to the prognostic model of
McNamara et al. [5] an anticipated recurrence
rate was calculated for the present case series.
For this study University Hospital of Ioannina
Ethics and Clinical Trials Review Committee
permission was granted according to the
Declaration of Helsinki Principles.
RESULTS
Twenty-seven patients were started on
intravenous daptomycin and 26 patients (15
male, 11 female; median age 68 years, range
38–89 years) who completed treatment were
followed up for recurrences. Depending on the
individual disease course the patients received
daptomycin for 7–14 days. One patient with
inadequate clinical cellulitis control at 48 h
after treatment initiation was excluded from
follow-up: treatment failure rate of daptomycin
3.7%. In the case of this single non-responder
cure was achieved by adding intravenous
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ceftriaxone (2 g/day; Rocephin, Roche Hellas
A.E.) to the treatment scheme. After
37–85 months follow-up one recurrence
occurred, that is, 96.2% of the patients
remained relapse-free at the end of follow-up
(95% CI 79.5–99.9%). The recurrence occurred
in a 70-year-old female patient with a left tibia
cellulitis and history of breast cancer (see
Table S1 in the supplementary material for a
compilation of core cohorts’ demographic and
disease parameters). It is worth noting that the
predicted recurrence free rate at 2 years
follow-up according to McNamara’s recurrence
score for lower leg cellulitis (73.5%) is outside
the 95% confidence range of the recurrence rate
observed in the present case series. However,
instead of the 2-year period of the above model
we presently considered follow-up
periods[3 years. Finally, considering overall
effectiveness of the treatment, 25/27 patients
initially treated with daptomycin for the first
lower leg cellulitis episode (92.6%; 95% CI
75.5–99.0%) remain recurrence free after more
than 3 years follow-up.
DISCUSSION
With the present three-week treatment
combination, in addition to a satisfactory
([95%) cure rate, we observed an optimistic
low disease recurrence rate after more than
3 years follow-up. The present observation
further supports our recent finding that the
treatment of the first cellulitis episode with a
3 week clindamycin scheme may reduce the risk
of subsequent recurrences [3]. Compared to
conventional treatment selections cure rate of
cellulitis with daptomycin are not inferior and
due to once daily bolus administration, this
agent could be also suitable for outpatient
parental antibiotic therapy [6, 7].
The pathogenesis of recurrent cellulitis
episodes is still poorly understood [1, 2].
Recurrent episodes of cellulitis generate
functional residua in the affected skin area that
predispose to subsequent disease episodes, thus
creating a vicious cycle. To date the concept of
modifying cellulitis recurrence risk by the
selection of different treatment schemes for the
first disease episode has not been adequately
addressed. However, the treatment choice for the
first cellulitis episode may confer protection
against the risk of future relapses by different
mechanisms: (1) Targeting bacterial protein
synthesis by the antibacterial scheme could
inhibit toxin synthesis and inflammatory
mediators production during infection and thus
protect tissues from excess damage (e.g.,
lymphedema perpetuation) [3, 4]; (2) prolonged
treatment duration ([2 weeks) may effectively
eradicate latent infection foci in the relatively
immunocompromised compartment of the tibial
skin [8, 9]; (3) It is further conceivable that the
pathogenetic potential of the infecting bacterial
strain, as denoted by the species and subspecies
status, could variably predispose to subsequent
relapses [10]. Daptomycin and roxithromycin
target a broader species spectrum than
traditional beta-lactam antibacterials.
This may be the first report of a long-term
follow-up for recurrences in patients who were
started on daptomycin for the first cellulitis
episode. This study is limited by retrospective
planning and the restricted number of included
patients. Future studies should explore
interventions for the first cellulitis episode as a
means to modify the risk of the frequently
detrimental recurring course of this disease.
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